Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,001 to 1,020 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Bioinformatics and Experimental Analysis of the Prognostic and Predictive Value of the CHPF Gene on Breast Cancer. | Front Oncol | 2022 | 35372047 | PubTator, text mining | PubMed |
| Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance. | Front Immunol | 2022 | 35371060 | PubTator, text mining | PubMed |
| Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas. | Front Immunol | 2022 | 35371015 | PubTator, text mining | PubMed |
| Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. | RSC Chem Biol | 2022 | 35360884 | PubTator, text mining | PubMed |
| Tissue-Dependent Adaptations and Functions of Innate Lymphoid Cells. | Front Immunol | 2022 | 35359972 | PubTator, text mining | PubMed |
| Integrative Pan-Cancer Analysis of KIF15 Reveals Its Diagnosis and Prognosis Value in Nasopharyngeal Carcinoma. | Front Oncol | 2022 | 35359374 | PubTator, text mining | PubMed |
| miR-484: A Potential Biomarker in Health and Disease. | Front Oncol | 2022 | 35356223 | PubTator, text mining | PubMed |
| Response of Human Liver Tissue to Innate Immune Stimuli. | Front Immunol | 2022 | 35355993 | PubTator, text mining | PubMed |
Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma. | Front Genet | 2022 | 35350243 | PubTator, text mining | PubMed |
| CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. | Nat Commun | 2022 | 35338135 | PubTator, text mining | PubMed |
| A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins. | Viruses | 2022 | 35337019 | PubTator, text mining | PubMed |
| A Novel Ferroptosis-Related lncRNAs Signature Predicts Clinical Prognosis and Is Associated With Immune Landscape in Pancreatic Cancer. | Front Genet | 2022 | 35330729 | PubTator, text mining | PubMed |
| Marked to Die-Cell Death Mechanisms for Keratinocyte Acantholysis in Pemphigus Diseases. | Life (Basel) | 2022 | 35330080 | PubTator, text mining | PubMed |
| Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia. | Int J Mol Sci | 2022 | 35328487 | PubTator, text mining | PubMed |
| The Forgotten Brother: The Innate-like B1 Cell in Multiple Sclerosis. | Biomedicines | 2022 | 35327408 | PubTator, text mining | PubMed |
Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. | Cancers (Basel) | 2022 | 35326747 | PubTator, text mining | PubMed |
| Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate. | Front Immunol | 2022 | 35320938 | PubTator, text mining | PubMed |
| CD3 engagement as a new strategy for allogeneic "off-the-shelf" T cell therapy. | Mol Ther Oncolytics | 2022 | 35317526 | PubTator, text mining | PubMed |
| Progression-Free Survival of a Patient with Advanced Hepatocellular Carcinoma Treated with Adoptive Cell Therapy Using Natural Killer Cells: A Case Report. | Onco Targets Ther | 2022 | 35313527 | PubTator, text mining | PubMed |
| 5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas. | Front Immunol | 2022 | 35309316 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=51